e-learning
resources
Munich 2014
Wednesday, 10.09.2014
Antibiotics, antifungals and other therapeutic options
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Bactericidal activity of ciprofloxacin dry powder for inhalation (DPI) in a hollow fiber (HF) model
S. Obertegger, G. Weskott, P. Surdakowski, K. Merfort, M. Glenschek-Sieberth (Wuppertal, Germany)
Source:
International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Session:
Antibiotics, antifungals and other therapeutic options
Session type:
Poster Discussion
Number:
4690
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Obertegger, G. Weskott, P. Surdakowski, K. Merfort, M. Glenschek-Sieberth (Wuppertal, Germany). Bactericidal activity of ciprofloxacin dry powder for inhalation (DPI) in a hollow fiber (HF) model. Eur Respir J 2014; 44: Suppl. 58, 4690
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Investigation of gram positive antibiotics as aerosol administration (cubicin, vancomycin, zyvoxid)
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa
Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections
Year: 2014
Study of adherence to the use of inhaled sodium colistimethate through the I-neb® nebulization system
Source: International Congress 2014 – Different interesting issues in respiratory infections: 1
Year: 2014
Serological-diagnosis of chronic pulmonary aspergillosis (CPA) and
aspergillus
lateral-flow device (LFD)
Source: International Congress 2014 – Cells, biofilms and biomarkers in respiratory infections
Year: 2014
The impact of mixed etiology in community acquired pneumonia (CAP)
Source: International Congress 2014 – Respiratory infections: inflammation and treatment
Year: 2014
Baseline profiles of subjects randomised in RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-CF bronchiectasis (NCFB) by pathogen and prior exacerbation rate
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
Efficacy of inhaled dry powder tobramycin (TOBI Podhaler) in P. aeruginosa infected patients with bronchiectasis - iBEST study
Source: Virtual Congress 2020 – Bronchiectasis: epidemiology, endotyping and therapy
Year: 2020
Inspiratory flow resistance of marketed dry powder inhalers (DPI)
Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases
Year: 2014
Effect of long term azithromycin on exacerbations in non CF bronchiectasis
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
LATE-BREAKING ABSTRACT: Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB)
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Year: 2015
Clinical cure rates in patients treated with azithromycin (AZ) for lower respiratory infections (LRTI) caused by AZ-susceptible (AZ-S) and AZ-resistant (AZ-R) organisms: Analysis of phase 3 clinical trials
Source: International Congress 2014 – Respiratory symptoms in primary care populations
Year: 2014
Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD
Source: Annual Congress 2012 - Hot topics in respiratory infections
Year: 2012
Modification of empirical antibiotic therapy in community acquired pneumonia
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
Breakthrough invasive pulmonary aspergillosis (IPA) in patients receiving posaconazole prophylaxis (PPxis)
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Year: 2015
Late Breaking Abstract - Lung deposition of two different ICS/LABA combinations with Dry Powder Inhaler (DPI) in asthmatic patients using Functional Respiratory Imaging (FRI).
Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update
Year: 2019
LATE-BREAKING ABSTRACT: Pneumococcal serotypes causing community-acquired pneumonia (CAP) among hospitalized adults in Spain using a new urinary antigen detection (UAD) test. The CAPA study
Source: International Congress 2014 – New technologies and biomarkers in lung disease
Year: 2014
Antimicrobial susceptibility of pseudomonasaeruginosa in CF patients before and after regular treatment with inhaled tobramycin
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015
Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI)
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015
Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept